Table 1.
Characteristics of patients that underwent allogeneic hematopoietic cell transplantation for NHL and HL reported to the CIBMTR between 2000 and 2010, by graft type.
| Characteristics of patients | MUD | MMUD | UCB | P-value |
|---|---|---|---|---|
| Number of patients | 1176 | 275 | 142 | |
| Age, median (range), years* | 50 (18-75) | 45 (18-71) | 45 (19-73) | <0.001 |
| Male sex* | 749 (64) | 164 (60) | 79 (56) | 0.106 |
| Karnofsky performance score* | 0.097 | |||
| <90% | 349 (30) | 98 (36) | 37 (26) | |
| ≥90% | 709 (60) | 152 (55) | 96 (68) | |
| Missing | 118 (10) | 25 ( 9) | 9 ( 6) | |
| Race* | <0.001 | |||
| Caucasian | 1122 (95) | 246 (89) | 110 (77) | |
| Black | 21 ( 2) | 16 ( 6) | 18 (13) | |
| Others** | 33 ( 3) | 13 ( 5) | 14 (10) | |
| Interval from diagnosis to transplant, months* | 34 (3-312) | 32 (3-247) | 27 (2-203) | 0.168 |
| Previous autologous transplant* | 485 (41) | 134 (49) | 64 (45) | 0.067 |
| Interval from autoHCT to alloHCT, months* | 20 (6-175) | 19 (6-154) | 18 (6-139) | 0.894 |
| Histology* | 0.074 | |||
| Hodgkin lymphoma | 233 (20) | 74 (27) | 39 (27) | |
| Follicular/ other indolent lymphoma | 294 (25) | 59 (21) | 30 (21) | |
| DLBCL/other aggressive B cell lymphoma | 282 (24) | 70 (25) | 39 (27) | |
| Mantle cell lymphoma | 212 (18) | 38 (14) | 13 ( 9) | |
| Mature T cell and NK cell neoplasm | 155 (13) | 34 (12) | 21 (15) | |
| Chemosensitive status prior to transplant* | 818 (69) | 183 (67) | 107 (76) | 0.201 |
| Disease status prior to transplant | 0.363 | |||
| First partial remission | 143 (12) | 27 (10) | 23 (16) | |
| PIF resistant | 128 (11) | 34 (12) | 13 ( 9) | |
| CR1 | 72 ( 6) | 13 ( 5) | 15 (11) | |
| Second partial remission | 315 (27) | 77 (28) | 34 (24) | |
| REL resistant | 230 (20) | 58 (21) | 22 (16) | |
| CR2+ | 220 (18) | 54 (20) | 26 (18) | |
| REL untreated/unknown | 26 ( 2) | 7 ( 2) | 2 ( 1) | |
| Missing | 42 ( 4) | 5 ( 2) | 7 ( 4) | |
| Prior radiation therapy* | 751 (64) | 194 (71) | 116(82) | <0.001 |
| Graft type* | NA | NA | ||
| Bone marrow | 259 (22) | 74 (27) | ||
| Peripheral blood | 913 (78) | 201 (73) | ||
| Recipient Cytomegalovirus serology* | 0.089 | |||
| Positive | 622 (53) | 136 (49) | 79 (56) | |
| Negative | 552 (47) | 138 (50) | 61 (43) | |
| Missing | 2 (<1) | 1 (<1) | 2 ( 1) | |
| One antigen/allele mismatch by locus | NA | NA | NA | |
| HLA-A | 78 (28) | |||
| HLA-B | 38 (14) | |||
| HLA-C | 130 (47) | |||
| HLA-DRB1 | 29 (11) | |||
| Donor-Recipient sex match | NA | NA | ||
| Male-Male | 531 (45) | 112 (41) | ||
| Male-Female | 277 (24) | 58 (21) | ||
| Female-Male | 189 (16) | 51 (19) | ||
| Female-Female | 132 (11) | 53 (19) | ||
| Year of transplant* | <0.001 | |||
| 2000-2003 | 338 (29) | 97 (35) | 21 (15) | |
| 2004-2006 | 463 (39) | 134 (49) | 34 (24) | |
| 2007-2010 | 375 (32) | 44 (16) | 87 (61) | |
| Conditioning regimen* | <0.001 | |||
| Myeloablative | 302 (26) | 81 (29) | 41 (29) | |
| Reduced intensity | 874 (74) | 194 (71) | 101 (71) | |
| Total number chemotherapy lines, median | 4 (1-5) | 4 (1-5) | 3 (1-5) | <0.001 |
| ATG/alemtuzumab* | <0.001 | |||
| ATG and alemtuzumab | 1 (<1) | 1 (<1) | 0 | |
| ATG alone | 296 (25) | 88 (32) | 51 (36) | |
| alemtuzumab alone | 138 (12) | 38 (14) | 1 ( 1) | |
| No ATG or alemtuzumab | 740 (63) | 148 (54) | 89 (63) | |
| Graft versus host disease prophylaxis* | <0.001 | |||
| Tacrolimus + others | 809 (69) | 179 (65) | 56 (39) | |
| Cyclosporine + others | 177 (15) | 43 (16) | 65 (46) | |
| Other*** | 28 ( 4) | 4 ( 3) | 7 ( 5) | |
| Median follow-up of survivors (range), months | 57 (6-129) | 65 (12-125) | 25 (6-73) |
Abbreviations: UCB umbilical cord blood; MUD matched unrelated donor; MMUD mismatched unrelated donor; DLBCL diffuse large B cell lymphoma, TBI total body irradiation, ATG antithymocyte globulin
*
Variables tested in Cox proportional hazards regression models.
**
Other race includes: Asian/Pacific Islander n=18 (UCB=7, MUD=8, MMUD=3), Middle East or Northcoast of Africa n=2 (MUD=1, MMUD=1), Hispanic n=5 (MUD=3, MMUD=2) and others (UCB=7, MUD=21, MMUD=7).
***
Other graft versus host disease prophylaxis includes: ATG only=1, ATG/Methotrexate=1, Methotrexate only=1, Missing=26.